Reference,Reference: DOI,Assay,Section,Pre-vaccine Infection,Vaccine,# Shots,Months,Host,Control,Control: NT50 Cmp,Control: NT50 GeoMean,Control: NT50 GSD,Variant,Variant: Pos,Variant: Mutations,# Results,Potency: NT50 Cmp,Potency: NT50 GeoMean,Potency: NT50 GSD,Fold Reduction: Cmp,Fold Reduction: Median
Gong21,10.1016/j.virol.2021.09.001,Pseudovirus (HIV),Figure 6,Wild Type,BNT162b2,1,1m,Human,Wild Type (B.1),=,1946.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,1358.0,1.0,=,1.4
Gong21,10.1016/j.virol.2021.09.001,Pseudovirus (HIV),Figure 6,Wild Type,BNT162b2,1,1m,Human,Wild Type (B.1),=,2004.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,837.0,1.0,=,2.4
Gong21,10.1016/j.virol.2021.09.001,Pseudovirus (HIV),Figure 6,Wild Type,BNT162b2,1,1m,Human,Wild Type (B.1),=,3354.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,1366.0,1.0,=,2.5
Gong21,10.1016/j.virol.2021.09.001,Pseudovirus (HIV),Figure 6,Wild Type,BNT162b2,1,1m,Human,Wild Type (B.1),=,4054.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,1849.0,1.0,=,2.2
Gong21,10.1016/j.virol.2021.09.001,Pseudovirus (HIV),Figure 6,Wild Type,BNT162b2,1,1m,Human,Wild Type (B.1),=,7841.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,7005.0,1.0,=,1.1